Original ArticleInternational Journal of Pharmaceutical InvestigationVol. 16 | Issue 3 | 2026 | pp. 1117–1122Open access
Evaluating the Awareness, Perceptions, and Practices of Clinical Trial Sponsors Regarding the Utilization of Human Leftover Biospecimens in Future Research
- 1*,
- 1,
- 1
- 1 Department of Pharmacy Practice, KLE College of Pharmacy, Belagavi, KLE Academy of Higher Education and Research, Belagavi, Karnataka, INDIA.
Published in International Journal of Pharmaceutical Investigation
Correspondence: Kurubara Amaresh
Department of Pharmacy Practice, KLE College of Pharmacy, Belagavi, KLE Academy of Higher Education and Research, Belagavi, Karnataka, INDIA.
Email: ambik365@gmail.com
Copyright: © 2026 Manuscript Technomedia. This is an open access article.
- Published:
- Jan 1, 2026
- Received:
- Feb 18, 2026
- Accepted:
- May 21, 2026
- DOI:
- 10.5530/ijpi.20260171
How to cite
Amaresh, K., Ganachari, M. S., & Devarinti, R. S. (2026). Evaluating the Awareness, Perceptions, and Practices of Clinical Trial Sponsors Regarding the Utilization of Human Leftover Biospecimens in Future Research. International Journal of Pharmaceutical Investigation, 16(3), 1117–1122. https://doi.org/10.5530/ijpi.20260171
Abstract
Background
Surplus human biospecimens serve as a valuable resource for advancing scientific discovery, and their ethical management is essential for maintaining integrity in biomedical research. Clinical Trial Sponsors hold a particularly important role in ensuring that these materials are handled in accordance with established ethical guidelines and regulatory frameworks. This study explores the level of awareness, perceptions, and practices among sponsors regarding the ethical use of leftover human biospecimens for future research purposes.
Materials and Methods
A forward-looking interventional study was conducted using a validated questionnaire administered to Clinical Trial Sponsors. Participants completed surveys before and after an educational intervention addressing ethical principles, regulatory mandates, and best-practice procedures related to biospecimen use. A follow-up assessment was carried out 30 days after the intervention. Data were analyzed using appropriate statistical tools, including a paired t-test, to compare pre- and post-intervention scores.
Results
A total of 52 participants took part in the study. Analysis revealed statistically significant improvements across all awareness, perceptions, and practices indicators following the intervention (p<0.001). Participants demonstrated greater clarity on essential ethical concepts, regulatory obligations, and correct biospecimen-handling procedures, indicating a strong positive effect of the educational program.
Conclusion
Targeted educational initiatives markedly strengthen the ethical understanding and responsible conduct of Clinical Trial Sponsors in the management of surplus human biospecimens. These findings emphasize the need for ongoing training efforts and continued policy enhancement to reinforce ethical foundations and ensure sustained regulatory compliance within biospecimen-based research.
Keywords
Subject
Article metadata
| Title | Evaluating the Awareness, Perceptions, and Practices of Clinical Trial Sponsors Regarding the Utilization of Human Leftover Biospecimens in Future Research |
|---|---|
| Authors | Kurubara Amaresh; Madiwalayya Shivakantayya Ganachari; Revana Siddappa Devarinti |
| Affiliations | Department of Pharmacy Practice, KLE College of Pharmacy, Belagavi, KLE Academy of Higher Education and Research, Belagavi, Karnataka, INDIA. |
| Corresponding author | ambik365@gmail.com |
| Journal | International Journal of Pharmaceutical Investigation |
| Volume / Issue | Vol. 16, Issue 3 (2026) |
Also in this issue
- Exploring Natural Bioactive Compounds for Radiation Countermeasure Properties: A Reviewpp. 770–778
- Exploring the Historical Dissemination and Contemporary Resurgence of Monkeypox: A Comprehensive Examination of its Evolution, Global Impact, and Treatment Approachespp. 779–787
- Engineering Smart Stimuli-Responsive Carriers for Precision Drug Delivery: Current Trends and Future Outlookpp. 788–799
- From Seizure Control to Parasite Management: Antiepileptic Drugs and Neurocysticercosispp. 800–807
- Preclinical Models of Hepatic Injury: A Comprehensive Review of Chemically, Immunologically, and Pharmacologically Induced Liver Damage in Rat Modelspp. 808–825